CSCIF (Cosciens Biopharma) Institutional Ownership: 0.12% (As of Jul. 01, 2026)


CSCIF Cosciens Biopharma Inc CSCIF
61 GF Score
Price $2.30
GF Value $2.34
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Institutional Ownership?

Cosciens Biopharma CSCIF +0.44% 61 Institutional Ownership is 0.12% as of Jul. 01, 2026. GuruFocus rates CSCIF with a GF Score™ of 61/100 and a GF Value™ of $2.34 (Fairly Valued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cosciens Biopharma's institutional ownership is 0.12%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cosciens Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cosciens Biopharma's Float Percentage Of Total Shares Outstanding is 99.58%.

Cosciens Biopharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Institutional Ownership Chart

Cosciens Biopharma Historical Data

The historical data trend for Cosciens Biopharma can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.03 0.03 0.03 0.03 0.02 0.01 0.01 0.01 0.01 0.01
CSCIF
61GF Score
Cosciens Biopharma Inc CSCIF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.12% mean?
Cosciens Biopharma (CSCIF) has a Institutional Ownership of 0.12% as of Jul. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Institutional Ownership too high?
Cosciens Biopharma's current Institutional Ownership is 0.12%. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Institutional Ownership compare to VRTX and REGN?
Cosciens Biopharma's Institutional Ownership of 0.12% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Institutional Ownership is 0.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Fairly Valued. The stock's GF Value™ is $2.34, compared to a current price of $2.30 — trading 1.7% below its estimated fair value. The current Institutional Ownership is 0.12%. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Institutional Ownership is 0.12% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $2.30 is trading 1.7% below its estimated GF Value™ of $2.34. GuruFocus considers Cosciens Biopharma to be Fairly Valued.

Key valuation signals for CSCIF:

  • Institutional Ownership: 0.12%
  • GF Value™: $2.34 vs. price of $2.30 (1.7% below fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score

Get the complete analysis for CSCIF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.30
Price
$2.34
GF Value